QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of Antiviral Drug Studies, Strategy Moving Forward
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a summary of its 2021 antiviral drug program so far this year, noting that all objectives in evaluating its proprietary DehydraTECH(TM) drug-delivery platform have been achieved. In addition, the company also discussed next steps. In short, the company stated that it has successfully tested and released summary results on five different compounds from three antiviral drug classes, with results gathered that indicate up to a threefold increase in oral drug delivery into the bloodstream upon animal testing when processed with DehydraTECH. According to the announcement, the company has been able…